First China Pharma Receives a Best Supplier and Best E-Comm Platform Award

KUNMING, CHINA--(Marketwire - July 27, 2011) - First China Pharmaceutical Group, Inc. (OTCBB: FCPG) (“First China” or the “Company”), a rapidly growing and technologically advanced healthcare products distributor based in Yunnan, China, is pleased to announce it has been recognized as Best Supplier and Best E-commerce purchasing platform of the Year 2011 by an influential regional association of professionals in the medical field.

First China was recently recognized in the categories of Best Supplier and Best E-commerce purchasing platform of the Year by the Kunming Private Hospital Association through a vote of its members based on product availability, product pricing, internet technical support, best on-time delivery as well as service quality and overall product satisfaction. First China is one of a select few suppliers to receive this honor.

The award is considered an influential vote of confidence and enjoys widespread industry recognition in Yunnan Province. As the health sector continues to enjoy rapid growth, both private and public sector facilities are constantly in need of distribution systems that fulfill their ongoing needs and are capable of growing to meet future demands. First China has made great strides in terms of identifying and meeting those needs and this award represents recognition of those efforts.

Mr. Wang Zhen Jiang, the Chairman and CEO of the Company, states, “We are very proud to receive this award and we remain committed to upholding this reputation by delivering our best to customers.”

Further details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information visit: www.firstchinapharma.com

About First China Pharmaceutical Group, Inc. (OTCBB: FCPG)
First China Pharmaceutical Group, Inc. aims to develop a high growth pharmaceutical distribution company generating significant revenue from the sale of healthcare products in China. As part of its business strategy, the Company has acquired the assets of Kun Ming Xin Yuan Tang Pharmacies Co. Ltd. (XYT), which includes a strategic advantage over its competitors as it is believed to be one of a limited number of pharmaceutical distribution companies in Yunnan Province that has obtained government approval to fulfill orders over the internet. First China Pharmaceutical Group plans to continue the rapid growth of the company from its current position as a provider of approximately 5,000 drugs to more than 4,700 pharmacies, hospitals and clinics in China’s Yunnan Province. For more information visit: www.firstchinapharma.com

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, regulatory incentives, the development of new business opportunities, and projected costs, revenue, profits and results operations. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: FCPG Pharma Care China Drug Distribution Pharmaceuticals Zhen Jiang Wang